Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Viralym-A
- Development stage
- Discontinued
- Lead developer
- Kalaris Therapeutics
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Tumor-Infiltrating Lymphocytes (TILs) → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
Viralym-A is an investigational T cell immunotherapy developed by AlloVir (formerly ViraCyte) for the treatment of Adenovirus infections in immunocompromised patients, particularly those who have undergone allogeneic stem cell transplant. It consists of banked Adenovirus-specific T cells derived from healthy donors, designed to specifically target and eliminate life-threatening Adenovirus infections that can occur when the immune system is weakened post-transplant. The drug is an investigational product not yet approved by the Food and Drug Administration (FDA).
02
Targets
Adenovirus-derived peptide-HLA complex
Beyond the preview
Go deeper on Viralym-A.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Viralym-A.